Source:http://linkedlifedata.com/resource/pubmed/id/19535968
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2010-1-22
|
| pubmed:abstractText |
Drug-induced hepatitis (DIH) is an important issue in tuberculosis (TB) treatment. We intend to assess the incidence, risk factors, and outcome of hepatitis due to anti-TB drugs. The study is carried out at the national TB referral center 2006-2008 including all documented new cases of TB. All patients received standard anti-TB treatment. If DIH occurred, all drugs were discontinued and reinitiated after liver function tests (LFT) normalization in a stepwise way. Of total 761 patients, 99 (13.0%) patients developed DIH during anti-TB treatment. There was no difference in sex, nationality, smoking, or opium use history between the hepatitis group and the control group (P > 0.05). DIH was significantly higher in patients older than 65 years (P = 0.019). The mean duration of DIH from the beginning of treatment was 17.53 +/- 19.42 days (median = 12; 1-125 days). Also, the mean of the time elapsed from DIH till the (LFT) normalization was 10.26 +/- 5.95 (median = 9; 0-32 days). Anorexia, nausea, vomiting, abdominal pain, jaundice, diarrhea, decreased level of consciousness, and fever were significantly higher in patients with DIH. In DIH group, 13 patients (13.4%) died, whereas in the control group, death occurred just in 21 cases (3.2%) (P < 0.001, 95% confidence interval = 2.26-9.70, odds ratio = 4.7). After adjusting with logistic regression, all the anticipated factors retained the statistical significance. Our study indicated that DIH most often occurs during the first 2 weeks of anti-TB treatment. DIH development is associated with old age, certain clinical manifestations, and higher death rates.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1536-3686
|
| pubmed:author |
pubmed-author:BaghaeiParvanehP,
pubmed-author:ChitsazEhsanE,
pubmed-author:FahimiFanakF,
pubmed-author:FarniaParisaP,
pubmed-author:KazempourMehdiM,
pubmed-author:MansouriDavoodD,
pubmed-author:MarjaniMajidM,
pubmed-author:MasjediMohammadrezaM,
pubmed-author:PooramiriMajid ValiollahMV,
pubmed-author:SalehMasoumehM,
pubmed-author:ShemiraniShahrzadS,
pubmed-author:TabarsiPayamP
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
17
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
17-22
|
| pubmed:meshHeading |
pubmed-meshheading:19535968-Adult,
pubmed-meshheading:19535968-Age Factors,
pubmed-meshheading:19535968-Aged,
pubmed-meshheading:19535968-Antitubercular Agents,
pubmed-meshheading:19535968-Drug-Induced Liver Injury,
pubmed-meshheading:19535968-Female,
pubmed-meshheading:19535968-Humans,
pubmed-meshheading:19535968-Liver Function Tests,
pubmed-meshheading:19535968-Logistic Models,
pubmed-meshheading:19535968-Male,
pubmed-meshheading:19535968-Middle Aged,
pubmed-meshheading:19535968-Risk Factors,
pubmed-meshheading:19535968-Tuberculosis, Pulmonary
|
| pubmed:articleTitle |
Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases.
|
| pubmed:affiliation |
Tuberculosis Department, Mycobacteriology Research Center, National Research Institute of Tuberculosis and Lung Disease, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. pbaghaei@nritld.ac.ir
|
| pubmed:publicationType |
Journal Article
|